The impact of HIV drug resistance testing on changes to treatment

AIDS

Volumn 25, Issue 5, 2011, Pages 603-610

  Bansi, Loveleen ^a   Smith, Colette ^a   Phillips, Andrew ^a   Kirk, Stuart ^b   Geretti, Anna Maria ^a   Johnson, Margaret ^a   MacKie, Nicola ^c   Post, Frank ^d   Gazzard, Brian ^e   Dunn, David ^f   Sabin, Caroline ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^c IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^d KING'S COLLEGE LONDON   (United Kingdom)

^e CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^f MRC CLINICAL TRIALS UNIT   (United Kingdom)

Author keywords

ART; genotypic sensitivity score; HAART; resistance; switch

Indexed keywords

ACICLOVIR; ADEFOVIR; ANTIRETROVIRUS AGENT; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ANTIVIRAL RESISTANCE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; DRUG TREATMENT FAILURE; FEMALE; GENOTYPE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; SCORING SYSTEM; SENSITIVITY ANALYSIS;

ADULT; ANTI-RETROVIRAL AGENTS; DATA COLLECTION; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; RETREATMENT; TREATMENT OUTCOME; VIRAL LOAD;

EID: 79952453762     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32834403a0     Document Type: Article

References (10)

1. Gazzard B. BHIVA guidelines 2008. HIV Med 2008; 9:563-608.
2. DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. http://www.aidsinfo.nih.gov/ ContentFiles/AdultandAdolescentGL.pdf; 2009 December 1.
3. Hirsch M, Gunthard H, Schapiro J, Brun-Vezinet F, Clotet B, Hammer S, et al. Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel. Clin Infect Dis 2008; 47:266-285. (Pubitemid 351920631)
4. UK CHIC SC. The creation of a large UK-based multicentre cohort of HIV-infected individuals: The UK Collaborative HIV Cohort (UK CHIC) Study. HIV Med 2004: 5:115-124.
5. Cingolani A, Antinori A, Rizzo MG, Murri R, Ammassari A, Baldini F, et al. Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA). AIDS 2002; 16:369-379. (Pubitemid 34165368)
6. Nieuwkerk P, Gisolf E, Sprangers M, Danner S. Adherence over 48 weeks in an antiretroviral clinical trial: variable within patients, affected by toxicities and independently predictive of virological response. Antivir Ther 2001; 6:97-103. (Pubitemid 32652094)
7. Lima VD, Harrigan R, Murray M, Moore DM, Wood E, Hogg RS, et al. Differential impact of adherence on long-term treatment response among naive HIV-infected individuals. AIDS 2008; 22:2371-2380.
8. Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000; 133:21-30. (Pubitemid 30432540)
9. Arnsten JH, Demas PA, Farzadegan H, Grant RW, Gourevitch MN, Chang CJ, et al. Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: comparison of selfreport and electronic monitoring. Clin Infect Dis 2001; 33:1417-1423. (Pubitemid 32955198)
10. Lee KJ, Dunn D, Gilson R, Porter K, Bansi L, Hill T, et al. Treatment switches after viral rebound in HIV-infected adults starting antiretroviral therapy: multicentre cohort study. AIDS 2008; 22:1943-1950.